Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9586183 | 0.91 | NQO1 (0.61) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL10017492 | 0.87 | DRD2 (0.40) | NQO1DRD2RAB9AHRH3CYP3A4 | |
| SCHEMBL10017493 | 0.86 | DRD2 (0.55) | MAOAMAOBDRD2MAPT | |
| SCHEMBL12990842 | 0.84 | ESR2 (0.53) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL10144013 | 0.83 | NQO1 (0.56) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL8595900 | 0.82 | NQO1 (0.50) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL10017496 | 0.82 | NQO1 (0.50) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL8595904 | 0.82 | SPHK1 (0.51) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL9349628 | 0.82 | NQO1 (0.50) | NQO1TSHRTDP1MAOAMAOB | |
| SCHEMBL11838572 | 0.82 | HRH3 (0.55) | NQO1TSHRTDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9470929-B2 | Liquid crystal display unit and method of manufacturing the same | SONY CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160011463-A1 | LIQUID CRYSTAL DISPLAY UNIT AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160011463-A1 | LIQUID CRYSTAL DISPLAY UNIT AND METHOD OF MANUFACTURING THE SAME | PYM1, PDCD2L, SDAD1 | NQO1 4833/4885TSHR 4188/4885TDP1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.